22/20. Patient Counselling Information- (2020) - No.22.Flortaucipir F18 -( TAUVID)- (May 2020)
Drug Name:
22/20. Patient Counselling Information- (2020) - No.22.Flortaucipir F18 -( TAUVID)- (May 2020)
List Of Brands:
Indication Type Description:
Indication:
PATIENT COUNSELING INFORMATION-
Radiation Risk- Advise patients of the radiation risk of TAUVID
Pregnancy- Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with TAUVID [see Use in Specific Populations (8.1)].
Lactation- Advise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant .
Manufactured for Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, Philadelphia, PA 19104 Copyright © 2020, Eli Lilly and Company. All rights reserved. 7.0-TAU-0000-USPI-202005DD